

Revision date 16-Nov-2020

Version 1.02

Page 1/10

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier	
Product Name	Pfizer-BioNTech COVID-19 Vaccine
Product Code(s) Synonyms	PF00092 PF-07302048 containing PF-07305885 (BNT162b2); CorVAC Containing PF-07305885 (BNT162b2) ; CoVVAC Containing PF-07305885 (BNT162b2); COVID Vaccine Containing PF-07305885 (BNT162b2); COVID-19 Vaccine Containing PF-07305885 (BNT162b2)
Trade Name: Compound Number Item Code Chemical Family:	Not applicable PF-07302048 H000022941: H000023057 Lipid Nanoparticles containing PF-07305885 (BNT162b2) and Lipids

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use

Pharmaceutical product

1.3. Details of the supplier of the safety data sheet

Pfizer Inc 235 East 42nd Street New York, New York 10017 1-800-879-3477 Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

1.4. Emergency telephone number

Emergency TelephoneChemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887E-mail addresspfizer-MSDS@pfizer.com

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture Not classified as hazardous

2.2. Label elements	
Signal word	Not classified
Hazard statements	Not classified in accordance with international standards for workplace safety.
<u>2.3. Other hazards</u> Other hazards	An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

NonHazardous

	50.11				
Chemical name	EC No	CAS No	Weight-%	Classification	REACH
				according to	Registration
				Regulation (EC) No.	Number
				1272/2008 [CLP]	
Water	231-791-2	7732-18-5	*	Not Listed	
Sucrose	200-334-9	57-50-1	< 10	Not Listed	
SODIUM CHLORIDE	231-598-3	7647-14-5	< 10	Not Listed	
ALC-0315	Not Listed	NOT ASSIGNED	< 2	Not Listed	
Potassium phosphate	231-913-4	7778-77-0	<1	Not Listed	
POTASSIUM CHLORIDE	231-211-8	7447-40-7	< 1	Not Listed	
PF-07305885	Not Listed	NOT ASSIGNED	<1	Not Listed	
PF-07302048	Not Listed	NOT ASSIGNED	< 1	Not Listed	
PEGA / ALC-0159	Not Listed	NOT ASSIGNED	< 1	Not Listed	
Disodium phosphate	Not Listed	10028-24-7	< 1	Not Listed	
dihydrate					
Cholesterol	200-353-2	57-88-5	< 1	Not Listed	
1,2-Distearoyl-sn-glycero-3	212-440-2	816-94-4	< 1	Not Listed	
-phosphocholine					

Full text of H- and EUH-phrases: see section 16

Additional information

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.		
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.		
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.		
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.		
4.2. Most important symptoms and effects, both acute and delayed			

Most important symptoms and	No data available
-----------------------------	-------------------

effects

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians	None.		
Section 5: FIRE-FIGHTING M	EASURES		
5.1. Extinguishing media			
Suitable Extinguishing Media	Dry chemical, CO2, alcohol-resistant foam or water spray.		
5.2. Special hazards arising from th	e substance or mixture		
Specific hazards arising from the chemical	Fine particles (such as mists) may fuel fires/explosions.		
Hazardous combustion products	Formation of toxic gases is possible during heating or fire.		
5.3. Advice for firefighters			
Special protective equipment for fire-fighters	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.		
Section 6: ACCIDENTAL RELEASE MEASURES			
6.1. Personal precautions, protective equipment and emergency procedures			

Personal precautions For emergency responders 6.2. Environmental precautions	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure. Use personal protection recommended in Section 8.
Environmental precautions	Place waste in an appropriately labeled, sealed container for disposal. Care should be
Environmental precautions	taken to avoid environmental release.
6.3. Methods and material for conta	ainment and cleaning up
Methods for containment Methods for cleaning up	Prevent further leakage or spillage if safe to do so. Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Prevention of secondary hazards	Clean contaminated objects and areas thoroughly observing environmental regulations.
6.4. Reference to other sections	
Reference to other sections	See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Restrict access to work area. No open handling permitted. Minimize generating airborne mists and vapors. If solvent based liquid, ground and bond all bulk transfer equipment. Use appropriate engineering controls to maintain exposures below the B-OEB taking all applicable routes of exposure into consideration. A change area to facilitate 'good laboratory/manufacturing' decontamination practices is recommended. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 16-Nov-2020

Page 4 / 10 Version 1.02

should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. **General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store at < -70 °C in properly labeled containers. Keep away from heat, sparks, and flames.

7.3. Specific end use(s)

Specific use(s)

Vaccine.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Sucrose ACGIH TLV Bulgaria Estonia France Ireland Latvia Spain OSHA PEL	10 mg/m ³ 10.0 mg/m ³ 10 mg/m ³ 10 mg/m ³ 10 mg/m ³ STEL: 20 mg/m ³ 5 mg/m ³ 10 mg/m ³ 15 mg/m ³ 5 mg/m ³ (vacated) TWA: 15 mg/m ³ total dust (vacated) TWA: 5 mg/m ³ respirable fraction
United Kingdom	TWA: 10 mg/m ³ STEL: 20 mg/m ³
SODIUM CHLORIDE Latvia Russia Potassium phosphate Russia POTASSIUM CHLORIDE Bulgaria Latvia Russia Pfizer OEB Statement:	5 mg/m ³ MAC: 5 mg/m ³ MAC: 10 mg/m ³ 5.0 mg/m ³ 5 mg/m ³ MAC: 5 mg/m ³ MAC: 5 mg/m ³ MAC: 5 mg/m ³
	Engineering control measures should be utilized to bring exposures into the relevant B-OEB; supplementary administrative controls and personal protective equipment are to be used to achieve exposure control to the bottom of the band.
SODIUM CHLORIDE Pfizer Occupational Exposure Band (OEB):	OEB 1 (control exposure to the range of 1000ug/m ³ to 3000ug/m ³)
POTASSIUM CHLORIDE Pfizer Occupational Exposure Band (OEB): PF-07305885	OEB 1 (control exposure to the range of 1000ug/m ³ to 3000ug/m ³)
Pfizer Occupational Exposure Band (OEB): PF-07302048	B-OEB Default (control exposure to the range of 10 μ g/day to <100 μ g/day)
Pfizer Occupational Exposure	B-OEB 5 (control exposure to <10 µg/day)

Band (OEB): 8.2. Exposure controls

Engineering controls	Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, biosafety cabinet, or other engineering controls to maintain airborne levels within the B-OEB range. It is recommended that all large scale operations should be fully enclosed. Air recirculation is not recommended.
Environmental exposure controls	No information available.
Personal protective equipment	Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Eye/face protection	Wear safety glasses as minimum protection (goggles recommended). (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Hand protection	Wear impervious disposable gloves (e.g. Nitrile, etc.) as minimum protection (double recommended). (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Wear impervious disposable protective clothing when handling this compound. Full body protection is recommended (scale dependent). Wear impervious protective clothing when handling this compound. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Biotherapeutic Occupational Exposure Band (B-OEB) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the B-OEB (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties Physical state Color Molecular formula Molecular weight	Liquid milky white Mixture Mixture
Odor	No data available.
Odor threshold	No data available
Property	Values
pH	7.4
Melting point / freezing point	No data available
Boiling point / boiling range	No data available
Flash point	No data available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 16-Nov-2020

Page 6/10 Version 1.02

Vapor pressure Vapor density Relative density Water solubility Solubility(ies) Autoignition temperature Decomposition temperature Kinematic viscosity Dynamic viscosity Explosive properties Oxidizing properties

9.2. Other information Liquid Density Bulk density No data available No data available

No data available No data available

Section 10: STABILITY AND REACTIVITY

<u>10.1. Reactivity</u> Reactivity	No data available.		
10.2. Chemical stability Stability Explosion data	Stable under normal conditions.		
Sensitivity to Mechanical Impac	t No data available.		
Sensitivity to Static Discharge	No data available.		
10.3. Possibility of hazardous react			
Possibility of hazardous reactions 10.4. Conditions to avoid	no information available.		
Conditions to avoid	Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.		
10.5. Incompatible materials Incompatible materials	As a precautionary measure, keep away from strong oxidizers.		
10.6. Hazardous decomposition products Hazardous decomposition products No data available.			
Section 11: TOXICOLOGICAL INFORMATION			
11.1. Information on toxicological effects			
General Information:	Toxicological properties have not been thoroughly investigated. The following information is		

Known Clinical Effects:

I oxicological properties have not been thoroughly investigated. The following information is available for the individual ingredients. Based on clinical trials in humans, possible adverse effects following intravenous exposure to this compound may include: muscle pain, abnormal redness of skin (erythema), fever, and sleep disturbances.

Acute Toxicity: (Species, Route, End Point, Dose) Sucrose Rat Oral LD 50 29,700 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³ Rat Oral LD 50 3 g/kg

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 16-Nov-2020

Mouse Oral LD 50 4 g/kg Rabbit Dermal LD 50 > 10 g/kg POTASSIUM CHLORIDE Rat Oral LD50 2600 mg/kg Potassium phosphate Rat Oral LD50 3200 mg/kg Rabbit Dermal LC50 > 4640 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Sucrose	= 29700 mg/kg (Rat)	-	-
SODIUM CHLORIDE	= 3 g/kg (Rat)	-	> 42 g/m³(Rat)1 h
Potassium phosphate	= 3200 mg/kg(Rat)	-	-
POTASSIUM CHLORIDE	= 2600 mg/kg (Rat)	-	-

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE Skin irritation Rabbit Mild Eye irritation Rabbit Mild POTASSIUM CHLORIDE Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

PF-07302048

4 Week(s) Rat Intramuscular * 10 μg LOAEL Skin, Blood forming organs, Blood, Skeletal muscle, Lymphoid tissue, Spleen **Repeated Dose Toxicity Comments: PF-07302048:** * Doses were administered once a week.

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Potassium phosphate

Reproductive & Fertility Rat No route specified 282 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus Reproductive & Fertility Mouse No route specified 320 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus

<u>Genetic Toxicity: (Study Type, Cell Type/Organism, Result)</u> <u>Potassium phosphate</u> Bacterial Mutagenicity (Ames) Salmonella Negative

Carcinogenicity	See below
Cholesterol	
IARC	Group 3 (Not Classifiable)

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result) POTASSIUM CHLORIDE

Gambusia affinis (Mosquitofish) LC50 96 hours 920 mg/l

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 16-Nov-2020

Lepomis macrochirus (Bluegill Sunfish) LC50 96 hours 2010 mg/L Daphnia Magna (Water Flea) EC50 48 hours 825 mg/l Scenedesmus subspicatus (Green Alga) EC50 72 Hours 2500 mg/L

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

No information available.

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does
	not apply
Potassium phosphate	The substance is not PBT / vPvB PBT assessment does
	not apply
POTASSIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does
	not apply
Cholesterol	The substance is not PBT / vPvB

12.6. Other adverse effects

Other adverse effects No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water	
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Sucrose	Not Listed Not Listed Present 231-791-2 Present
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS	Not Listed Not Listed Present 200-334-9 Present
SODIUM CHLORIDE CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS	Not Listed Not Listed Present 231-598-3 Present
ALC-0315 CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS Potassium phosphate	Not Listed Not Listed Not Listed
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS	Not Listed Not Listed Present 231-913-4 Present
POTASSIUM CHLORIDE CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Not Listed Not Listed Present 231-211-8 Present Schedule 4
PF-07305885 CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS PF-07302048	Not Listed Not Listed Not Listed
CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS PEGA / ALC-0159	Not Listed Not Listed Not Listed
CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS Disodium phosphate dihydrate	Not Listed Not Listed Not Listed
CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS AICS	Not Listed Not Listed Not Listed Present
Standard for Uniform Scheduling of Medicines and	Schedule 5

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 16-Nov-2020

Poisons (SUSMP)	
Cholesterol	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	200-353-2
AICS	Present
Standard for Uniform Scheduling of Medicines and	Schedule 4
Poisons (SUSMP)	
1,2-Distearoyl-sn-glycero-3-phosphocholine	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	212-440-2
15.2. Chemical safety assessment	

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Data Sources:	Pfizer proprietary drug development information. Publicly available toxicity information.
Reason for revision	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Revision date	16-Nov-2020
Prepared By	Product Stewardship Hazard Communication Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.